Abstract
We performed a prospective, open study to evaluate the clinical effect of Carvedilol among pediatric patients with myocardial failure (CHF) failing to reply sufficiently to standard therapy. In addition, we assessed pharmacokinetic parameters of Carvedilol among these children. Pediatric patients were treated with oral Carvedilol in a ramped dosing scheme (initially 0.09mg/kg day followed by 0.18, 0.35 for two weeks each and 0.70mg/kg day as a target dose) in addition to ACE inhibitors, digoxin and diuretics. Clinical parameters (ejection fraction, modified Ross score) were assessed in a blinded manner before initiation of treatment and monthly up to six months. Pharmacokinetic profiles of Carvedilol were determined over the first 12-hour period following the initial dose and over another 12-hour period under steady state conditions following the target dose. Sixteen patients (between 6 weeks and 19 years of age) were enrolled in the study, including 10 patients with dilated cardiomyopathy and six with myocardial failure secondary to congenital heart diseases. All 16 patients tolerated the maximum target dose. After six months of Carvedilol therapy, ejection fraction was increased (37 ± 18% to 52 ± 21%; p < 0.05) and the modified Ross score was improved (5 ± 2 to 3 ± 3 points; p < 0.05). Elimination half-life (t1/2) was 2.6 hours (range 1.49 to 3.66) in young (0.1 to 3.5 years of age, n = 7) and 5.3 hours (3.71 to 6.93; p < 0.05) in older pediatric patients (5.5 to 19 years of age, n = 7; p < 0.05). Overall, pediatric patients with CHF and failing standard therapy had a benefit from oral Carvedilol treatment. The increased elimination of Carvedilol in young children suggests that an increase in dosing might further improve the therapeutic response.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, Tikanoja T, Paavilainen T, Simell O. 1997. Epidemiology of idiopathic cardiomyopathies in children and adolescents. Am J Epidemiol 146:385–393.
Dec GW, Fuster V. 1994. Idiopathic dilated cardiomyopathy. A review. N Engl J Med 331:1564–1575.
Packer M, Bristow M, Cohn JN for the US Carvedilol heart failure study group. 1996. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355.
Frishman WH. 1998. Carvedilol. Drug therapy. N Engl J Med 339:1759–1765.
MERIT-HE 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007.
CIBIS II Investigators and committees. 1999. The cardiac insufficiency bisoprolol study II (CIBIS-II); a randomised trial. Lancet 353:9–13.
Snider RA, Bengur AR. 1992. Doppler echocardiography. In: Moss AJ and Adams FH, eds. Heart disease in infants, children, and adolescents. Wiliams and Wilkens, 270–292.
Matitiau A, Perez-Atayde A, Sanders SP, Sluysmans T, Parness IA, Spevak PJ, Colan SD. 1994. Infantile dilated cardiomyopathy. Relation of outcome to left ventricular mechanics, hemodynamics, and histology at the time of presentation. Circulation 90:1310–1318.
Ross RD. 1992. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 13:72–75.
Reithmann C, Reber D, Kozlik-Feldmann R, Netz H, Pilz G, Welz A, Werdan K. 1997. Post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Eur J Pharmacol 330:79–86.
Kukin ML, Kaiman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, Eng C. 1999. Prospective, randomized comparison of effect of long-term treatment with metoprolol or Carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation 99:2645–2651.
Behn F, Läer S, Mir TS, Scholz H. 2001. HPLC quantification of Carvedilol in small plasma volumes from children. Chromatographia 53:641–644.
Shaddy RE, Lloyd YT, Gidding SS, et al. 1999. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: A multi-institutional experience. J Heart Lung Transplant 18:269–274.
Ishikawa Y, Bach JR, Minami R. 1999. Cardioprotection for Duchenne s muscular dystrophy. Am Heart J 137:895–902.
Läer S, Mir TS, Behn F, Scholz H, Eiselt M, Venske A, Meibohm B, Weil J. 2002 β-Receptor blocker therapy in pediatric patients with congestive heart failure: A study with Carvedilol investigating clinical and pharmacokinetic parameters. Am Heart J 43:916–922.
Lewis AB. 1999. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. Am Heart J 138:334–338.
Krumm H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. 1995. Double-blind, placebocontrolled study of the long term efficacy of Carvedilol in patients with chronic heart failure. Circulation 92:1499–1506.
Packer M. 1998. β-Adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog Cardiovasc Dis 41(Suppl l):39–52.
McTavish D, Campoli-Richards D, Sorkin EM. 1993. Carvedilol. A review of ist pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45:232–258.
Morselli PL. 1989. Clinical pharmacology of the perinatal period and early infancy, Clin Pharma-cokinet 17(Suppl 1): 13–28.
Wilkinson GR, Shand DG. 1975. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390.
Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OFW 1989. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9:297–301.
Murray DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. 1995. Liver volume as determinant of drug clearance in children and adolescents. Drug Metabol Disp 10:1110–1116.
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. 1996. Carvedilol produces doserelated improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807–2816.
DiLenarda A, Sabbadini G, Salvatore L and the heart muscle disease study group. 1999. Long-term effects of Carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 33:1926–1934.
Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. 1993. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342:1441–1446.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Scholz, H., Läer, S., Behn, F., Eiselt, M., Mir, T.S., Weil, J. (2003). Effects of the Beta-Adrenoceptor Blocker Carvedilol in Children with Myocardial Failure. In: Singal, P.K., Dixon, I.M.C., Kirshenbaum, L.A., Dhalla, N.S. (eds) Cardiac Remodeling and Failure. Progress in Experimental Cardiology, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9262-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9262-8_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4864-1
Online ISBN: 978-1-4419-9262-8
eBook Packages: Springer Book Archive